All In Biotech

Drug Trial Radar · NCT05125224

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Dihydropyridine Calcium Channel Blockers Versus Hydrochlorothiazide

Last checked: Nov 19, 2026Latest source record: Nov 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

163,720

Actual

Start

Oct 1, 2021

Primary completion

Jul 7, 2023

Study completion Dec 31, 2023

Sponsor

Lead sponsor
Brigham and Women's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Aging (NIA); Rutgers University; Johns Hopkins University
First posted
Nov 18, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years

Summary

As written by the sponsor on the registry.

This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

Conditions

  • Hypertension

Interventions

  • Dihydropyridine calcium channel blockerDrug

    Dihydropyridine calcium channel blocker claim is used as the exposure group.

  • HydrochlorothiazideDrug

    Hydrochlorothiazide claim is used as the reference group.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Dementia OnsetTime frame: Median follow up times: 1) 189 days (exp), 171 days (ref) 2) 835 days (exp). 851 days (ref) 3) 388 days (exp), 348 days (ref) 4) 191 days (exp), 172 days (ref)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Brigham and Women's Hospital

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.